Clinical Trial Update: Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluated bendamustine as second-line therapy for relapsed or refractory small cell lung cancer, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Bendamustine (Treanda) (bendamustine)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-03-12